

ExpreS2ion to Participate in BIO Hong Kong and H.C. Andersen Capital Institutional Investor Seminar in September

Hørsholm, Denmark, 31 August 2026 – ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate in two upcoming events in September 2026: BIOHK2026 and a H.C. Andersen Capital Seminar on Danish Equities for Institutional Investors.

These events provide an opportunity to present ExpreS2ion's technology platform and development pipeline to investors and industry participants. More details, including event registration information, are available on the [Company's website](#) and via the links below. To arrange a meeting at these events, please contact us at partnering@expres2ionbio.com or investor@expres2ionbio.com.

9-12 September 2026 | BIOHK2026: Hong Kong International Biotechnology Conference and Exhibition

Hong Kong

ExpreS2ion will attend BIOHK2026, the 5th Hong Kong International Biotechnology Conference and Exhibition, held at the Hong Kong Convention and Exhibition Centre. The event gathers global pharmaceutical companies including GSK, AstraZeneca, Novartis, Merck, Novo Nordisk and Pfizer alongside leading Chinese biotechnology innovators, together with investors, academic researchers and regional biomedical hubs from across the Asia-Pacific region.

The Company will take part as a member of the Nordic Pavilion, a delegation of Nordic life science companies organised in collaboration with the Hong Kong Biotechnology Organization and the Hong Kong Chamber of Commerce in Sweden.

ExpreS2ion will use the conference for partnering meetings and business development discussions on ES2B-C001 and the Company's *Drosophila* S2 expression platform. Investors and potential partners attending the conference who wish to arrange a meeting are welcome to contact the Company.

Further information is available at bio-hk.com.

17 September 2026 | H.C. Andersen Capital Seminar on Danish Equities for Institutional Investors

Copenhagen

ExpreS2ion will present at H.C. Andersen Capital's seminar on Danish equities for private wealth, semi-institutional and institutional investors. The seminar brings together listed Danish companies and more than 100 investors for a day of company presentations and networking.

ExpreS2ion's presentation will cover the Company's clinical progress, partnered programmes, platform activities and financial position.

Registration and further information are available from H.C. Andersen Capital.

Certified Adviser
Redeye Nordic Growth AB

For further information about Expres2ion, please contact:

Bent U. Frandsen, CEO

Keith Alexander, CFO

E-mail: investor@expres2ionbio.com

About Expres2ion

Expres2ion is a biotechnology company focused on the development of innovative active immunotherapies and vaccines for cancer and infectious diseases. The company has developed the Expres2™ platform, a proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle (VLP) projects spanning research, diagnostics, and therapeutic development. Proteins produced using the Expres2 platform are being evaluated in multiple clinical programmes worldwide. The platform has also been applied in partnered development programmes that have progressed into late-stage clinical evaluation, including Phase III studies that have met their primary endpoints. The platform, marketed as GlycoX-S2™, includes functionally modified glycosylation variants designed to enhance immunogenicity and pharmacokinetics. Expres2ion develops novel VLP-based vaccines in association with AdaptVac ApS, of which Expres2ion owns 34%. Expres2ion Biotech Holding AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.